摘要
目的比较经动脉灌注化疗栓塞(TACE)联合射频消融(RFA)与单独TACE或RFA治疗无法手术切除肝细胞癌(UHCC)的临床疗效。方法收集国内外关于TACE+RFA与单独TACE或RFA治疗UHCC的随机、对照临床研究文献(RCT),采用RevMan4.2软件,对符合纳入标准的8个独立性研究进行Meta分析,分析的主要对象为生存期及肿瘤完全坏死率。结果 TACE+RFA较单独TACE提高患者1年、2年及3年生存率(均P<0.01),较单独RFA提高1年及2年生存率(P=0.03、P<0.01),而3年生存率则缺乏统计学差异(P=0.16);而对于肿瘤完全坏死率,联合治疗明显较低(均P<0.01)。结论 TACE联合RFA治疗UHCC的疗效较单独TACE或单独RFA治疗好,而远期疗效较单独TACE能有效提高患者生存率,较单独RFA能提高1年及2年生存率。
Objective To compare the therapeutic effects of transcatheter arterial ehemoembolization （TACE） plus radiofrequency ablation （RFA） to TACE or RFA alone for unresectable hepatocellular carcinoma （UHCC）. Methods All data of patients with UHCC underwent TACE＋RFA versus TACE or RFA in random- ized-controlled clinical trials （RCT） were collected from literature by electronic searching. Meta-analysis that recommended was done for the data of 8 researches enrolled in criteria by using RevMan 4.2 software in this study. Objects were survival and rate of complete tumor necrosis. Results TACE＋RFA group had a statistically higher rate in 1-, 2-, 3-year survival compared with that of TACE group （all P〈0.01）. It also had a higher rate in 1-, 2-year survival than RFA group （P=0.03, P〈0.01）, but not in 3-year survival （P=-0.16）. As to the rate of complete tumor necrosis, combined therapy was better than either monotherapy （both P〈0.01）. Conclusions The local efficacy of TACE plus RFA for UHCC is better than either monotherapy. As to the prospective efficacy combined therapy can elevate the patients＇ survival rate compared with that of TACE alone and prolong patients＇ 1-, 2-year survival time compared with that of RFA alone. But there is no statistic different in 3-year patients＇ survival rate when TACE plus RFA compared to RFA alone.
出处
《中华普通外科学文献（电子版）》
2011年第1期51-54,共4页
Chinese Archives of General Surgery(Electronic Edition)
基金
广东省自然科学基金(07001663)
广东省科技计划(2009B030801027)
